Macleod A D
Department of Psychological Medicine, Christchurch School of Medicine, New Zealand.
J Pain Symptom Manage. 1998 Sep;16(3):193-8. doi: 10.1016/s0885-3924(98)00071-2.
Major depressive disorder in 26 hospice inpatients was managed with a trial of methylphenidate (mean daily dosage, 17.7 mg). A therapeutic response was achieved in 46% of the sample. However, a significant response was obtained in only 7% of those patients who subsequently died of their terminal illness within 6 weeks. Higher dosage psychostimulants may be indicated in the last weeks of life of the terminally ill. Alternatively "vital exhaustion" may account for the poor response rate in the treatment of depression in patients with advanced malignancy.
对26名临终关怀住院患者的重度抑郁症进行了哌甲酯试验治疗（平均每日剂量为17.7毫克）。46%的样本获得了治疗反应。然而，在随后6周内因绝症死亡的患者中，只有7%获得了显著反应。对于晚期绝症患者，在生命的最后几周可能需要使用更高剂量的精神兴奋剂。或者，“生命耗竭”可能是晚期恶性肿瘤患者抑郁症治疗反应率低的原因。
